Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Bevacizumab in Advanced Hepatocellular Carcinoma
NCT05886257Phase 2Withdrawn
- Sponsor
- Shiming Biotech
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Shiming Biotech. Primary endpoint: Objective Response Rate at 12 months. Planned start Dec 2022; status: withdrawn.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05886257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886257.